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Introduction
During antibiotic treatments a fraction of the dose impacts
the intestinal microbiota, promoting spread of resistant
bacteria (RB). Antibiotics can be inactivated by adsorption.
DAV132 is an oral medical device to deliver an adsorbent
in the late ileum. We investigated if DAV132 could reduce
fecal antibiotics and RB excreted.
Methods
Three models were used. First, to explore the relationship
between antibiotic exposure and excretion of RB, piglets
just received 15 or 1.5 mg/Kg/d of oral ciprofloxacin or
placebo X 5 days. We then compared between groups fecal
ciprofloxacin concentrations and the amount of RB
excreted. Second, to explore colonic adsorption of antibio-
tics by DAV132 in the colon, dogs received 10.7 mg/kg/d
of IV levofloxacin X 5 days together with 0.3 or 0.6 g/kg/d
or placebo of oral DAV132. We then compared between
groups fecal and blood levofloxacin concentrations. Last, to
explore if DAV132 could restore antibiotic-associated
disruption of colonization resistance (CR), mice received
300 mg/kg/d of sc cefotaxime or placebo X 3 days, together
with 50 mg/d or placebo of oral DAV131 (DAV132
adapted to the mice), followed by gastric challenge with
106 CFU of a K. pneumoniae resistant to third generation
cephalosporin (C3GR-Kp). We then compared between
groups fecal cefotaxime and C3GR-Kp concentrations.
Results
In piglets, counts of RB excreted were 9.2, 8.8 and 6.2
log10 CFU in animals receiving respectively the 15, the
1.5 mg/kg/d and the placebo regimen respectively
(p<0.001). In dogs, reduction of fecal levofloxacin
reached 71 and 82% when 0.3 or 0.6 g/kg/d of DAV132
was given. Blood PK of levofloxacin was not modified sig-
nificantly. In mice, all antibiotic disappeared from the
pellets when DAV131 was given to the animals together
with cefotaxime and a significant part of RC by C3GR-Kp
was restored.
Conclusion
Oral DAV132 might reduce exposure of the intestinal
flora by antibiotics which could be associated with
decrease in fecal excretion of RB without affecting blood
PK. There appeared to be a relationship between the dose
of DAV132 administered and the effect observed. The
possible clinical use of DAV132 is under investigation.
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